{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:25:45Z","timestamp":1793881545661,"version":"4.7.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T00:00:00Z","timestamp":1692576000000},"content-version":"vor","delay-in-days":1054,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s13311-020-00941-3","type":"journal-article","created":{"date-parts":[[2020,10,6]],"date-time":"2020-10-06T11:02:48Z","timestamp":1601982168000},"page":"1660-1664","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Update on the Treatment of Ataxia: Medication and Emerging Therapies"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7208-2418","authenticated-orcid":false,"given":"Susan L.","family":"Perlman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1007\/s13311-020-00941-3_bib1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ejpn.2019.08.004","article-title":"A clinical diagnostic algorithm for early onset cerebellar ataxia","volume":"23","author":"Brandsma","year":"2019","journal-title":"Eur J Paediatr Neurol."},{"issue":"3","key":"10.1007\/s13311-020-00941-3_bib2","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/practneurol-2018-002096","article-title":"Diagnosis and management of progressive ataxia in adults","volume":"19","author":"de Silva","year":"2019","journal-title":"Pract Neurol."},{"key":"10.1007\/s13311-020-00941-3_bib3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/B978-0-444-64189-2.00010-X","article-title":"Spinocerebellar ataxias","volume":"155","author":"Soong","year":"2018","journal-title":"Handb Clin Neurol."},{"issue":"6","key":"10.1007\/s13311-020-00941-3_bib4","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1007\/s12311-019-01052-2","article-title":"The Classification of Autosomal Recessive Cerebellar Ataxias: a Consensus Statement from the Society for Research on the Cerebellum and Ataxias Task Force","volume":"18","author":"Beaudin","year":"2019","journal-title":"Cerebellum."},{"issue":"3","key":"10.1007\/s13311-020-00941-3_bib5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s11065-010-9142-x","article-title":"The role of the cerebellum in cognition and emotion: personal reflections since 1982 on the dysmetria of thought hypothesis, and its historical evolution from theory to therapy","volume":"20","author":"Schmahmann","year":"2010","journal-title":"Neuropsychol Rev."},{"issue":"3","key":"10.1007\/s13311-020-00941-3_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11940-019-0549-2","article-title":"The Comprehensive Management of Cerebellar Ataxia in Adults","volume":"21","author":"Stephen","year":"2019","journal-title":"Curr Treat Options Neurol."},{"issue":"3","key":"10.1007\/s13311-020-00941-3_bib7","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1590\/0004-282x20190020","article-title":"Acute cerebellar ataxia: differential diagnosis and clinical approach","volume":"77","author":"Pedroso","year":"2019","journal-title":"Arq Neuropsiquiatr."},{"issue":"1","key":"10.1007\/s13311-020-00941-3_bib8","doi-asserted-by":"crossref","first-page":"e1814","DOI":"10.1002\/pri.1814","article-title":"Changes in standing stability with balance-based torso-weighting with cerebellar ataxia: A pilot study","volume":"25","author":"Widener","year":"2020","journal-title":"Physiother Res Int."},{"issue":"5","key":"10.1007\/s13311-020-00941-3_bib9","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s12311-019-01063-z","article-title":"Exercise and Physical Therapy Interventions for Children with Ataxia: A Systematic Review","volume":"18","author":"Hartley","year":"2019","journal-title":"Cerebellum."},{"key":"10.1007\/s13311-020-00941-3_bib10","first-page":"CD004963","article-title":"Exercise for improving balance in older people","volume":"11","author":"Howe","year":"2011","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"10.1007\/s13311-020-00941-3_bib11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s12311-013-0514-7","article-title":"Non-invasive cerebellar stimulation\u2013a consensus paper","volume":"13","author":"Grimaldi","year":"2014","journal-title":"Cerebellum."},{"issue":"8","key":"10.1007\/s13311-020-00941-3_bib12","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1016\/j.clinph.2018.06.003","article-title":"Transcranial magnetic stimulation in hereditary ataxias: Diagnostic utility, pathophysiological insight and treatment","volume":"129","author":"Rodriguez-Labrada","year":"2018","journal-title":"Clin Neurophysiol."},{"key":"10.1007\/s13311-020-00941-3_bib13","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3389\/fneur.2019.00073","article-title":"Repetitive Transcranial Magnetic Stimulation in Spinocerebellar Ataxia: A Pilot Randomized Controlled Trial","volume":"10","author":"Manor","year":"2019","journal-title":"Front Neurol."},{"issue":"2","key":"10.1007\/s13311-020-00941-3_bib14","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.brs.2016.11.001","article-title":"Long term clinical and neurophysiological effects of cerebellar transcranial direct current stimulation in patients with neurodegenerative ataxia","volume":"10","author":"Benussi","year":"2017","journal-title":"Brain Stimul."},{"issue":"12","key":"10.1007\/s13311-020-00941-3_bib15","doi-asserted-by":"crossref","first-page":"e1090","DOI":"10.1212\/WNL.0000000000006210","article-title":"Cerebello-spinal tDCS in ataxia: A randomized, double-blind, sham-controlled, crossover trial","volume":"91","author":"Benussi","year":"2018","journal-title":"Neurology."},{"issue":"6","key":"10.1007\/s13311-020-00941-3_bib16","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1007\/s12311-019-01041-5","article-title":"Consensus Paper: Experimental Neurostimulation of the Cerebellum","volume":"18","author":"Miterko","year":"2019","journal-title":"Cerebellum."},{"issue":"4","key":"10.1007\/s13311-020-00941-3_bib17","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1159\/000504062","article-title":"Long-Term Suppression of Disabling Tremor by Thalamic Stimulation in a Patient with Spinocerebellar Ataxia Type 2","volume":"97","author":"Isobe","year":"2019","journal-title":"Stereotact Funct Neurosurg."},{"issue":"10","key":"10.1007\/s13311-020-00941-3_bib18","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1212\/WNL.0000000000005055","article-title":"Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Zesiewicz","year":"2018","journal-title":"Neurology."},{"issue":"3","key":"10.1007\/s13311-020-00941-3_bib19","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.neuro.2009.02.014","article-title":"Co-treatment with riluzole, a neuroprotective drug, ameliorates the 3-acetylpyridine-induced neurotoxicity in cerebellar Purkinje neurones of rats: behavioural and electrophysiological evidence","volume":"30","author":"Janahmadi","year":"2009","journal-title":"Neurotoxicology."},{"issue":"1","key":"10.1007\/s13311-020-00941-3_bib20","doi-asserted-by":"crossref","first-page":"e00007","DOI":"10.1002\/prp2.7","article-title":"Effects of D-amino acid oxidase inhibition on memory performance and long-term potentiation in vivo","volume":"1","author":"Hopkins","year":"2013","journal-title":"Pharmacol Res Perspect."},{"key":"10.1007\/s13311-020-00941-3_bib21","doi-asserted-by":"crossref","unstructured":"Ronnefarth M, Hanisch N, Brandt AU, Mahler A, Endres M, Paul F, et al. Dysphagia Affecting Quality of Life in Cerebellar Ataxia-a Large Survey. Cerebellum. 2020.","DOI":"10.1007\/s12311-020-01122-w"},{"issue":"1","key":"10.1007\/s13311-020-00941-3_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40263-013-0124-4","article-title":"Mitochondrial enhancement for neurodegenerative movement disorders: a systematic review of trials involving creatine, coenzyme Q10, idebenone and mitoquinone","volume":"28","author":"Liu","year":"2014","journal-title":"CNS Drugs."},{"issue":"4","key":"10.1007\/s13311-020-00941-3_bib23","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2217\/nmt-2018-0013","article-title":"Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia","volume":"8","author":"Zesiewicz","year":"2018","journal-title":"Neurodegener Dis Manag."},{"issue":"2","key":"10.1007\/s13311-020-00941-3_bib24","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1002\/mds.26088","article-title":"Coenzyme Q10 and spinocerebellar ataxias","volume":"30","author":"Lo","year":"2015","journal-title":"Mov Disord."},{"key":"10.1007\/s13311-020-00941-3_bib25","doi-asserted-by":"crossref","unstructured":"Yu M, Bega D. A Review of the Clinical Evidence for Complementary and Alternative Medicine in Huntington's Disease. Tremor Other Hyperkinet Mov (N Y). 2019;9.","DOI":"10.5334\/tohm.509"},{"issue":"1","key":"10.1007\/s13311-020-00941-3_bib26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.7861\/clinmedicine.13-1-7","article-title":"Adverse effects of herbal medicines: an overview of systematic reviews","volume":"13","author":"Posadzki","year":"2013","journal-title":"Clin Med (Lond)."},{"issue":"3","key":"10.1007\/s13311-020-00941-3_bib27","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00228-012-1353-z","article-title":"Contamination and adulteration of herbal medicinal products (HMPs): an overview of systematic reviews","volume":"69","author":"Posadzki","year":"2013","journal-title":"Eur J Clin Pharmacol."},{"issue":"2","key":"10.1007\/s13311-020-00941-3_bib28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12311-013-0539-y","article-title":"Consensus paper: pathological mechanisms underlying neurodegeneration in spinocerebellar ataxias","volume":"13","author":"Matilla-Duenas","year":"2014","journal-title":"Cerebellum."},{"issue":"4","key":"10.1007\/s13311-020-00941-3_bib29","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1007\/s13311-019-00764-x","article-title":"Molecular Mechanisms and Therapeutics for the GAA.TTC Expansion Disease Friedreich Ataxia","volume":"16","author":"Gottesfeld","year":"2019","journal-title":"Neurotherapeutics."},{"issue":"2","key":"10.1007\/s13311-020-00941-3_bib30","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.ncl.2020.01.008","article-title":"An Overview of the Current State and the Future of Ataxia Treatments","volume":"38","author":"Kwei","year":"2020","journal-title":"Neurol Clin."},{"issue":"4","key":"10.1007\/s13311-020-00941-3_bib31","first-page":"695","article-title":"Selective Neuronal Death in Neurodegenerative Diseases: The Ongoing Mystery","volume":"92","author":"Subramaniam","year":"2019","journal-title":"Yale J Biol Med."},{"key":"10.1007\/s13311-020-00941-3_bib32","doi-asserted-by":"crossref","unstructured":"Andreone BJ, Larhammar M, Lewcock JW. Cell Death and Neurodegeneration. Cold Spring Harb Perspect Biol. 2020;12(2).","DOI":"10.1101\/cshperspect.a036434"},{"key":"10.1007\/s13311-020-00941-3_bib33","doi-asserted-by":"crossref","first-page":"964518","DOI":"10.1155\/2015\/964518","article-title":"Mechanisms of Neuronal Protection against Excitotoxicity, Endoplasmic Reticulum Stress, and Mitochondrial Dysfunction in Stroke and Neurodegenerative Diseases","volume":"2015","author":"Prentice","year":"2015","journal-title":"Oxid Med Cell Longev."},{"issue":"2","key":"10.1007\/s13311-020-00941-3_bib34","first-page":"25","article-title":"Precision medicine in spinocerebellar ataxias: treatment based on common mechanisms of disease","volume":"4","author":"Bushart","year":"2016","journal-title":"Ann Transl Med."},{"issue":"24","key":"10.1007\/s13311-020-00941-3_bib35","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1007\/s00018-013-1415-0","article-title":"Therapeutic neuroprotective agents for amyotrophic lateral sclerosis","volume":"70","author":"Pandya","year":"2013","journal-title":"Cell Mol Life Sci."},{"issue":"10","key":"10.1007\/s13311-020-00941-3_bib36","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S1474-4422(15)00201-X","article-title":"Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Romano","year":"2015","journal-title":"Lancet Neurol."},{"issue":"2","key":"10.1007\/s13311-020-00941-3_bib37","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41419-017-0153-x","article-title":"Functional and structural damage of neurons by innate immune mechanisms during neurodegeneration","volume":"9","author":"Ising","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1007\/s13311-020-00941-3_bib38","doi-asserted-by":"crossref","unstructured":"Barake F, Soza A, Gonzalez A. Galectins in the brain: advances in neuroinflammation, neuroprotection and therapeutic opportunities. Curr Opin Neurol. 2020.","DOI":"10.1097\/WCO.0000000000000812"},{"issue":"4","key":"10.1007\/s13311-020-00941-3_bib39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s12640-012-9315-x","article-title":"Targeting neuro-inflammatory cytokines and oxidative stress by minocycline attenuates quinolinic-acid-induced Huntington's disease-like symptoms in rats","volume":"22","author":"Kalonia","year":"2012","journal-title":"Neurotox Res."},{"issue":"1","key":"10.1007\/s13311-020-00941-3_bib40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s12311-015-0697-1","article-title":"Transplantation and Stem Cell Therapy for Cerebellar Degenerations","volume":"15","author":"Cendelin","year":"2016","journal-title":"Cerebellum."},{"key":"10.1007\/s13311-020-00941-3_bib41","doi-asserted-by":"crossref","unstructured":"Akhlaghpasand M, Tizro M, Raoofi A, Meymand AZ, Farhadieh M, Khodagholi F, et al. Grafted human chorionic stem cells restore motor function and preclude cerebellar neurodegeneration in rat model of cerebellar ataxia. Metab Brain Dis. 2020.","DOI":"10.1007\/s11011-020-00543-0"},{"issue":"3","key":"10.1007\/s13311-020-00941-3_bib42","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.mehy.2014.05.022","article-title":"Autologous stem cell transplant with gene therapy for Friedreich ataxia","volume":"83","author":"Tajiri","year":"2014","journal-title":"Med Hypotheses."},{"issue":"3","key":"10.1007\/s13311-020-00941-3_bib43","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3727\/096368916X694373","article-title":"Treatment of Spinocerebellar Ataxia With Mesenchymal Stem Cells: A Phase I\/IIa Clinical Study","volume":"26","author":"Tsai","year":"2017","journal-title":"Cell Transplant."},{"key":"10.1007\/s13311-020-00941-3_bib44","doi-asserted-by":"crossref","first-page":"14044","DOI":"10.1038\/mtm.2014.44","article-title":"An AAV9 coding for frataxin clearly improved the symptoms and prolonged the life of Friedreich ataxia mouse models","volume":"1","author":"Gerard","year":"2014","journal-title":"Mol Ther Methods Clin Dev."},{"key":"10.1007\/s13311-020-00941-3_bib45","doi-asserted-by":"crossref","unstructured":"Perez BA, Shutterly A, Chan YK, Byrne BJ, Corti M. Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases. Brain Sci. 2020;10(2).","DOI":"10.3390\/brainsci10020119"},{"issue":"2","key":"10.1007\/s13311-020-00941-3_bib46","doi-asserted-by":"crossref","first-page":"e323","DOI":"10.1212\/NXG.0000000000000323","article-title":"Antisense oligonucleotides: A primer","volume":"5","author":"Scoles","year":"2019","journal-title":"Neurol Genet."},{"issue":"5","key":"10.1007\/s13311-020-00941-3_bib47","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/gt.2016.89","article-title":"Deletion of the GAA repeats from the human frataxin gene using the CRISPR-Cas9 system in YG8R-derived cells and mouse models of Friedreich ataxia","volume":"24","author":"Ouellet","year":"2017","journal-title":"Gene Ther."},{"issue":"11","key":"10.1007\/s13311-020-00941-3_bib48","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1089\/scd.2017.0209","article-title":"CRISPR\/Cas9-Targeted Deletion of Polyglutamine in Spinocerebellar Ataxia Type 3-Derived Induced Pluripotent Stem Cells","volume":"27","author":"Ouyang","year":"2018","journal-title":"Stem Cells Dev."},{"issue":"5","key":"10.1007\/s13311-020-00941-3_bib49","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1074\/jbc.TM118.004162","article-title":"Milestones in transcription and chromatin published in the Journal of Biological Chemistry","volume":"294","author":"Gottesfeld","year":"2019","journal-title":"J Biol Chem."},{"key":"10.1007\/s13311-020-00941-3_bib50","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.omtm.2019.10.008","article-title":"Development of an AAV-Based MicroRNA Gene Therapy to Treat Machado-Joseph Disease","volume":"15","author":"Martier","year":"2019","journal-title":"Mol Ther Methods Clin Dev."},{"key":"10.1007\/s13311-020-00941-3_bib51","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fnmol.2019.00156","article-title":"The Emerging Role of microRNAs in Polyglutamine Diseases","volume":"12","author":"Dong","year":"2019","journal-title":"Front Mol Neurosci."},{"key":"10.1007\/s13311-020-00941-3_bib52","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/B978-0-444-64189-2.00015-9","article-title":"Epigenetic cerebellar diseases","volume":"155","author":"Serrano","year":"2018","journal-title":"Handb Clin Neurol."},{"issue":"5","key":"10.1007\/s13311-020-00941-3_bib53","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1055\/s-0031-1299786","article-title":"Epigenetics in nucleotide repeat expansion disorders","volume":"31","author":"He","year":"2011","journal-title":"Semin Neurol."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00941-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-020-00941-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923012643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-020-00941-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:02:49Z","timestamp":1761807769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923012643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1878747923012643"],"URL":"https:\/\/doi.org\/10.1007\/s13311-020-00941-3","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on the Treatment of Ataxia: Medication and Emerging Therapies","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-020-00941-3","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}